Milestone Pharmaceuticals
MIST
43 hedge funds and large institutions have $43.6M invested in Milestone Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
9% more capital invested
Capital invested by funds: $39.9M → $43.6M (+$3.7M)
8% more funds holding
Funds holding: 40 → 43 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
2.83% less ownership
Funds ownership: 56.66% → 53.83% (-2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$130K |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$48.3K |
| 3 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$44.2K |
| 4 |
Millennium Management
New York
|
+$41.6K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$33.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
-$998K |
| 2 |
ACM
Altium Capital Management
New York
|
-$833K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$348K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$254K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$125K |
MIST Hedge Fund Activity: Q3 2024 in Review
43 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q3 2024, worth a combined $43.6M — up 9.3% from $39.9M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MIST positions and 1 closed out — a net gain of 3 holders — while 9 added to existing stakes and 9 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $130K. The largest seller was Lion Point Capital, cutting an estimated $998K.
- 43 institutional investors held Milestone Pharmaceuticals (MIST) as of Q3 2024, up from 40 in Q2 2024.
- Funds reported $43.6M of Milestone Pharmaceuticals stock for Q3 2024, up 9.3% quarter-over-quarter.
- 4 funds opened new Milestone Pharmaceuticals positions in Q3 2024 and 1 closed out, a net change of +3 holders.
- The largest Milestone Pharmaceuticals buyer in Q3 2024 was Morgan Stanley, an estimated $130K added.
- The largest Milestone Pharmaceuticals seller in Q3 2024 was Lion Point Capital, an estimated $998K sold.
Based on aggregated 13F filings for Q3 2024.